The $325 Million Neurontin (GABApentin) Open Class Action Settlement and What It Reveals About Big Pharma’s Hidden Marketing Practices
Learn about the 2010's Gabapentin open class action settlement
By Steve Levine | OpenClassActions.com
When Pfizer agreed to pay $325 million to settle claims over its anti-seizure drug Neurontin (gabapentin), it wasn’t just another corporate fine. It was the result of one of the longest and most consequential battles over off-label marketing in pharmaceutical history. The case peeled back the layers of how drug companies use influence, money, and selective science to drive prescriptions—and how insurers and consumers end up paying the price.
This settlement, approved by a federal court in Massachusetts, resolved allegations that Pfizer and its subsidiary Warner-Lambert (which originally developed Neurontin before Pfizer acquired it) deceptively marketed the drug for uses never approved by the U.S. Food and Drug Administration.
How Neurontin Became a Blockbuster—By Breaking the Rules
Neurontin was originally approved in the early 1990s as a treatment for epilepsy. But within a few years, the drug began appearing in prescriptions for everything from bipolar disorder to migraines and neuropathic pain. These were not FDA-approved uses. They were what’s known as off-label uses—meaning doctors can legally prescribe the drug that way, but manufacturers are not legally allowed to promote it for those conditions.
That distinction became the heart of the lawsuit. According to court filings, Pfizer (and before that Warner-Lambert) orchestrated a massive marketing campaign that encouraged doctors to prescribe Neurontin for unapproved uses by relying on misleading data, paid physician speakers, and biased research papers.
Internal company emails unearthed during the litigation described “education campaigns” and “thought leader” programs that were less about scientific accuracy and more about persuasion. The company allegedly funded studies designed to exaggerate Neurontin’s benefits while suppressing unfavorable findings.
By the early 2000s, Neurontin had turned into a multi-billion-dollar brand. Estimates suggest that as much as 90% of its prescriptions were for off-label uses.
The Legal Fight: Who Sued and Why
Unlike many drug lawsuits, this one wasn’t filed by patients. It was led by third-party payors—insurance companies, union health funds, and employer benefit plans that reimburse the cost of prescriptions. They argued that Pfizer’s conduct caused them to pay billions for medically unnecessary or ineffective prescriptions.
The lawsuit claimed that Pfizer’s marketing misled doctors and inflated demand for Neurontin, driving costs for insurers and healthcare systems nationwide. After years of discovery, expert testimony, and appeals, Pfizer ultimately agreed to a $325 million settlement, covering payments made between December 11, 2002, and August 31, 2008.
The settlement followed several related actions. In 2004, Pfizer paid $430 million in criminal and civil penalties to resolve U.S. Department of Justice allegations that Warner-Lambert illegally promoted Neurontin. A few years later, direct purchasers of the drug—primarily wholesalers and distributors—secured their own $190 million settlement.
The class action involving the $325 million fund focused specifically on indirect purchasers—entities that paid for or reimbursed Neurontin prescriptions through insurance or health benefit plans.
What the Settlement Means
Pfizer did not admit wrongdoing as part of the settlement, but the payout closed one of the final chapters of a decades-long legal saga. The funds were distributed to qualifying payors that could show they purchased or reimbursed for Neurontin or its generic equivalent, gabapentin, during the covered period.
The case also became a teaching moment in both legal and healthcare circles. It highlighted how marketing, rather than science, can shape medical practice—and how difficult it is for payors and patients to discern whether a prescription is truly evidence-based.
The legal theories used in the Neurontin litigation also helped pave the way for future cases involving false marketing, antitrust violations, and data manipulation in the pharmaceutical industry. In fact, many of the same attorneys and law firms who litigated Neurontin later became key players in opioid, antidepressant, and insulin price-fixing lawsuits.
Why Neurontin Still Matters Today
Even though Neurontin remains on the market—and continues to be prescribed widely—its legal history remains a cautionary tale. It serves as an example of how corporate influence can distort medical decision-making and how long it takes for accountability to catch up.
Pfizer’s legal exposure didn’t end with Neurontin, either. The company would go on to face lawsuits over Chantix, Zoloft, and other drugs, all raising similar questions about marketing ethics and public trust.
But perhaps the biggest takeaway is how off-label promotion has evolved. While the FDA continues to restrict direct marketing of unapproved uses, the rise of “educational content,” physician consulting, and digital influencer programs has blurred the line between information and advertising. The Neurontin case remains one of the few examples where those blurred lines led to concrete financial consequences.
A Legacy of Legal and Ethical Lessons
The $325 million Neurontin settlement may seem small compared to the pharmaceutical industry’s massive profits, but its symbolic weight endures. It was one of the first times a drug company faced a nationwide class action for off-label marketing—and lost.
It also set precedent for how courts handle the intersection of marketing, medicine, and money. Third-party payors now routinely monitor manufacturer behavior more closely, and regulators use cases like Neurontin as frameworks for enforcement.
More importantly, it gave the public a rare window into the machinery of Big Pharma—how corporate incentives can override patient outcomes, and how difficult it is to untangle truth from promotion once a drug becomes a household name.
Bottom line:
The Neurontin case wasn’t just about one drug. It was about an industry learning, sometimes reluctantly, that evidence and ethics matter as much as profits.
Thanks
Is there still a open class action lawsuit against gabapentin. I was looking to join